Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-08-30
2005-08-30
Smith, L. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S250100, C514S001000
Reexamination Certificate
active
06936261
ABSTRACT:
The present invention generally provides methods and vaccines for the prevention of diseases caused byNeisseria meningitidisbacteria, particularly serogroup B strains.
REFERENCES:
patent: 4601903 (1986-07-01), Frasch
patent: 4727136 (1988-02-01), Jennings et al.
patent: 5597572 (1997-01-01), Huergo et al.
patent: 5705161 (1998-01-01), Van Der Ley et al.
patent: 5747653 (1998-05-01), Huergo et al.
patent: 6180111 (2001-01-01), Stein et al.
patent: 0 449 958 (1995-03-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO 98/02547 (1998-01-01), None
patent: WO 98/56901 (1998-12-01), None
patent: WO 99/57280 (1999-04-01), None
patent: WO 99/24578 (1999-05-01), None
patent: WO 99/36544 (1999-07-01), None
patent: WO 99/61053 (1999-12-01), None
patent: WO 00/66791 (2000-02-01), None
patent: WO 00/22430 (2000-04-01), None
patent: WO 01/09350 (2001-02-01), None
patent: WO 01/34642 (2001-05-01), None
patent: WO 01/37863 (2001-05-01), None
Artenstein MS, et al, “Prevention of meningococcal disease by group C polysaccharide vaccine.” N Engl J Med 1970;282:417-20.
Balmer P, et al, “Serologic correlates of protection for evaluating the response to meningococcal vaccines,” Expert Rev Vaccines 2004;3:77-87.
Borrow R, et al, “Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection,” Infect Immun 2001;69:1568-73.
Densen P., “Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae,”Clin Microbiol Rev 1989;2 Suppl:S11-7.
De Wals P, et al, “Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec,” Jama 2001;285:177-81.
Figueroa JE, et al, “Infectious diseases associated with complement deficiencies,” Clin Microbiol Rev 1991;4:359-95.
Fijen CA, et al, “Complement deficiencies in patients over ten years old with meningocaccal disease due to uncommon serogroups,” Lancet 1989;2:585-8.
Frasch CE. “Meningococcal Vaccines: Past, Present and Future,” In: Cartwright K, ed. Meningococcal Disease. New York: John Wiley & Sons, 1995:245-83.
Gold R, et al, “Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70,” Bull World Health Organ 1971;45:279-82.
Goldschneider I, et al, “Human immunity to the meningococcus. II. Development of natural immunity,” J Exp Med 1969;129:1327-48.
Harris SL, et al, “Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine,” Infect Immun 2003;71:275-86.
Hoist et al., Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-737.
Maslanka SE, et al. “Age-dependentNeissena meningitidisserogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine,” Infect Immun 1998;66:2453-9.
Milagres LG, et al., “Immune response of Brazilian children to aNeisseria meningitidisserogroup B outer membrane protein vaccine: comparison with efficacy,” Infect Immun 1994;62:4419-24.
Moe et al., Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999 67:5664-75.
Nicholson A, Lepow IH. “Host defense againstNeisseria meningitidisrequires a complement-dependent bactericidal activity,” Science 1979;205:298-9.
Pollard AJ, et al, “Development of natural immunity toNeisseria meningitides,” Vaccine 2001;19:1327-46.
World Health Organization. Requirements for meningococcal polysaccharide vaccine (requirements for biological substances No. 23). WHO Tech Rep Ser 1976;594:72-73.
50 Fed. Reg. 162, Guidelines for Production of Meningococal Polysaccharide Vaccines, Notice of Availability Published Aug. 21, 1985.
Ashton, F. E. et al., 1938, “A New Serogroup (L) ofNeisseria meningitdis”, J. Clin. Microbiol.17: 722-727.
Borrow, et al., 2001, “Serological Basis for Usse of Meningococcal Serogroup C Conjugate Vaccines in the U.K.:Reevaluation of Correlates of Protection”,Infection and Immunity,69(3):1568-1573.
Branham, S. E., 1956, “Milestones in the History of Meningocoggus”,Canadian Journal of Microbiology, 2:175-188.
Campagne et al. 2000, “Safety and immunogenicity of three doses of aNeisseria meningitidesA+C diphtheria conjugate vaccine in infants from Niger”,Pediatric Infectious Disease Journal,19(2):144-150.
Cartwright K et al, 1999, “Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins”,Vaccine,17:2612-2619.
De Kleinjn ED et al, 2000, “Immunogenicity and safety of a hexavalent meningococcal outermembrane-vesicle vaccine in children of 2-3 and 7-8 years of age”,Vaccine, 18:1456-1466.
Frasch, C. E. and Chapman, 1973, “Classification ofNeisseria meningitidisGroup B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers”Journal of Infectious Disease, 127:149-154.
Fusco et al., 1997, “Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman Primates”,Journal of Infectious Diseases, 175: 364-372.
Gold et al., 1969-1970, “Meningococcal Infections”Bull. WHO, 45: 272-282.
Goldschneider et al, 1969, “Human Immunity to the Meningococcus: I. The Role of the Humoral Antibodies”J. Exp. Med.129:1307-1326.
Gotschlich et al., 1969, “Human Immunity to the Meningococcus: III. Preparation and Immunochemical Properties of the Group A, Group B, and Group C Meningococcal Polysaccharides”,J. Exp. Med.129:134-136.
Granoff et al., 1998, “Bacterial Monoclonal Antibodies That Define Unique Meningococcal B Polysaccharide Epitopes That Do Not Cross-React with Human Polysialic Acid”,J. Immunol; 160: 5028-5036.
Granoff et al., 1998, “Induction of Immunologic Refractoriness in Adults by Meningococcal C Polysaccharide Vaccination”,J. Infect. Dis.178(3): 870-4.
Hankins, 1982, Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A,C,Y, and W135 (41306),Proc. Soc. Biol. Med.169:54-57.
Hong et al., 1981, “Inhibitory Effect of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on the C3b Inactivator System”J Immunol.127:104-108.
MacDonald et al., 1998, “Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine In Toddlers”,JAMA280:1685-1689.
MacDonald et al., 2000, “Can Meningococcal C Conjugate Vaccine Overcome Immune Hyporesponsiveness Induced by Previous Administration of Plain Polysaccharide Vaccine?” JAMA 283:1826-1827.
Maclennan et al., 2000, “Safety, Immunogenicity, and Induction of Immunologic memory by a Serogroup C Meningococcal Conjugate Vaccine in Infants” JAMA 283: 2795-2801.
Maiden et al., 1998, “Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms”,Proc. Natl. Acad. Sci.USA 95:3140-3145.
Martin et al., 2000. “Candidate Neisseria meningitidis NspA vaccine”,J. Biotechnol.83:27-31.
Martin et al, 2000. “Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine”,Vaccine, 18:2476-2481.
Moe et al. 1999,“Differences in Surface Expression of NspA among Neisseria meningitidis Group B Strains”,Infection and Imnunity, 67:5664-5675.
Moe et al. 2001, “Functional Activity of Anti-Neisserial Surface Protein A Monoclonal Antibodie
Granoff Dan
Moe Gregory R.
Bozicevic Field & Francis LLP
Children's Hospital & Research Center at Oakland
Francis Carol L.
Smith L. F.
Zeman Robert A.
LandOfFree
Vaccines for broad spectrum protection against diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines for broad spectrum protection against diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines for broad spectrum protection against diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463870